Rheumatoid arthritis patients with therapy-induced myelodysplastic syndrome present with long-term remission after recovery [1]

Scandinavian Journal of Rheumatology

Volumn 36, Issue 2, 2007, Pages 149-151

  Thonhofer, R ^a,d   Kriessmayr, M ^b   Thonhofer, U ^b   Wipfler, E ^b   Uitz, E ^a   Bahadori, B ^a   Eder, S ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b GENERAL HOSPITAL KLAGENFURT   (Austria)

^c Styrean Health Insurance ^*  (Austria)

^d State Hospital Muerzzuschlag   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTYRAMINE; DIPYRONE; FLUCONAZOLE; IMIPENEM; LEFLUNOMIDE; METHOTREXATE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID;

BED REST; BONE MARROW BIOPSY; CANDIDA ALBICANS; CASE REPORT; COLLAPSE; CYTOPENIA; DISEASE ACTIVITY; FEMALE; FEVER; HUMAN; LETTER; LEUKOPENIA; LOW DRUG DOSE; MOUTH ULCER; MYELODYSPLASTIC SYNDROME; PHYSIOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SEPTICEMIA; SORE THROAT; STAPHYLOCOCCUS AUREUS; STOMATITIS; THROAT DISEASE; THROAT ULCER;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIPYRONE; FEMALE; HUMANS; ISOXAZOLES; METHOTREXATE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 34247557142     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740600844506     Document Type: Letter

References (10)

1. Okamoto H, Teramura M, Kamatani N. Myelodysplastic syndrome associated with low-dose methotrexate in rheumatoid arthritis. Ann Pharmacother 2004;38:172-3.
2. Kuitunen T, Malmstrom J, Palva E, Pettersson T. Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register from 1991 to 1999. Scand J Rheumatol 2005;34:238-41.
3. Ibanez L, Vidal X, Ballarin E, Laporte JR. Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 2005;60:821-9.
4. Vlahov V, Bacracheva N, Tontcheva D, Naumova E, Mavrudieva M, Ilieva P, et al. Genetic factors and risk of agranulocytosis frommetamizol. Pharmacogenetics 1996;6:67-72.
5. Ikehara S. Bone marrow transplantation: a new strategy for intractable diseases. Drugs Today 2002;38:103-11.
6. Snowden JA, Kearney P, Kearney A, Cooley HM, Grigg A, Jacobs P, et al. Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum 1998;41:453-9.
7. Snowden JA, Biggs JC, Milliken ST, Fuller A, Staniforth D, Passuello F, et al. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis. Bone Marrow Transplant 1998;22:1035-41.
8. Burt RK, Fassas A, Snowden J, van Laar JM, Kozak T, Wulffraat NM, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 2001;28:1-12.
9. Van Laar JM, Tyndall A. Intense immunosuppression and stem-cell transplantation for patients with severe rheumatic autoimmune disease: a review. Cancer Control 2003;10:57-65.
10. van Oosterhout M, Verburg RJ, Levarht EW, Moolenburgh JD, Barge RM, Fibbe WE, et al. High dose chemotherapy and syngeneic stem cell transplantation in a patient with refractory rheumatoid arthritis: poor response associated with persistence of host autoantibodies and synovial abnormalities. Ann Rheum Dis 2005;64:1783-5.